Abstract: The present invention relates to dosage forms of gallium complexes suitable for oral delivery and methods of preparation thereof. Such dosage forms are useful for the treatment of diseases, including, but not limited to, cancer.

Abstract: The invention relates to pharmaceutical compositions for direct systemic introduction, are also known as DSI pharmaceutical compositions, for used as human veterinary pharmaceutical compositions. In one embodiment, the invention relates to a pharmaceutical composition for direct system introduction comprising bovine gelatin, mannitol, an optional surfactant, an optional flavorant, and an active pharmaceutical ingredient. A DSI pharmaceutical composition of the invention has a disintegration time of 7 seconds or less in deionized water maintained at 37.0° C.±0.5° C. The invention also relates to a method of delivering an active pharmaceutical ingredient to an animal comprising the step of placing a DSI pharmaceutical composition of the invention into a mucosal cavity of an animal to be treated with the active pharmaceutical ingredient and to the corresponding methods of treatment.

Abstract: The invention relates to compositions and devices which include an osmolytic agent, in particular a betaine or carnitine compound, for reducing ocular discomfort associated with various diseases or conditions, in particular diseases or conditions associated with high tear film tonicity. The invention also relates to methods of treating or preventing various diseases or conditions using compositions and devices of the invention.

Abstract: Use of a compound of formula (I): wherein A, X, Y, R1 and R2 as defined herein, in treating hereditary angioedema is disclosed. A composition containing the compounds, a polar organic solvent or a mixture thereof; and optionally a co-solvent, is also disclosed.

Abstract: Method of administering compositions comprising omega 3 fatty acids for use in the treatment, amelioration or prevention of various conditions, disorders, and diseases which involve damage to the nervous system.

Abstract: In the present invention, a new combination is disclosed comprising (i) 5-aminosalicylic acid (5-ASA) or a derivative thereof, or a pharmacologically acceptable salt thereof, and (ii) a group D vitamin, a derivative thereof, a metabolite or analogue, for use in the prevention and/or treatment of colorectal cancer (CRC). A further aspect of the invention is directed to pharmaceutical compositions comprising said combination together with at least one physiologically acceptable excipient and the use thereof in the prevention and/or in the treatment of the colorectal cancer.

Abstract: The present invention encompasses immediate release tablets of dofetilide, methods of treatment with them, as well as a process for manufacturing the same.

Abstract: Provided herein are low salt ophthalmic pharmaceutical composition and methods of use thereof, for example, in the treatment of dry eye syndrome.

Abstract: Kits for allowing pharmacist to easily compound medications are provided. The kits include a mixing container, a first active ingredient and an inactive ingredient. It is further provided that methods of mixing compounds. Some kits include coloring agents that aid in the establishment proper mixing. Other kits include colored labels located on the ingredients.

Abstract: The present invention relates to a process to improve the yield of strawberry crops, the process comprising the step of applying a polyene antifungal agent, especially natamycin, to the roots of a strawberry plant prior to planting said plant and/or to the medium to which the plant is to be planted. The claimed process results in an increased number of crop, an increase in the weight of individual crop, and an increase in the total weight of the crop, and may allow for an earlier harvest.

Abstract: The invention provides a topical o/w emulsion which moisturizes, and protects, repairs or restores the skin lipid barrier of a mammal. The topical o/w emulsion composition comprises a discontinuous oil phase; a continuous aqueous phase comprising water; a thickening agent; at least one lamellar membrane structure comprising a phospholipid, a fatty alcohol, and a fatty acid; and wherein in use the composition has a water vapor transmission rate of less than about 70 g·m?2·hr?1 measured in vitro using the modWVTR test methodology.

Abstract: An antiperspirant stick composition can include a synthetic wax, a fatty alcohol, a hydrophilic surfactant having a hydrophilic-lipophilic balance (HLB) value greater than 10, a plasticizer present in an amount to minimize hardening of the composition due to contact with an aqueous composition, and an effective amount of an antiperspirant active agent. The hydrophilic surfactant can be present in an amount sufficient to minimize perspiration-induced discoloration of fabric in contact with the composition. The fatty alcohol and the antiperspirant active agent can be present at a weight ratio of from about 2:1 to about 1:2.

Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

Abstract: An aluminum-free antiperspirant/deodorant composition is disclosed. The aluminum-free antiperspirant/deodorant composition may include an oil-in-water emulsion base and an antiperspirant active dispersed in the oil-in-water emulsion base. The antiperspirant active may be primarily an amino acid, calcium carbonate and optionally a zinc-based antiperspirant active and the oil-in-water emulsion base may include an emulsifier having a mixture of steareth-2 and steareth-20; a plant-based oil, a polyol, and water. The zinc-based antiperspirant active may be free of zinc oxide-amino acid-halide complexes, amino acid-halides, and chelated zinc oxide complexes.

Abstract: This invention relates to methods and compositions for use improving cell viability, particularly neural cell viability, and more particularly to methods and compositions for use improving cell viability by reducing reactive oxygen metabolite-mediated oxidative damage in a cell, regulating redox homeostasis in a cell, or reducing mitochondrial dysfunction in a cell. The invention further relates to the administration of the bile acid tauroursodeoxycholic acid (TUDCA) in combination with phenylbutyric Acid (PBA) to improve cell viability, and treat at least one symptom associated with, prevent the time of onset of, or slow the development of a disease related to oxidative stress.

Abstract: Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.

Abstract: A pharmaceutical composition comprises a taxane (e.g., paclitaxel, docetaxel, cabazitaxel, larotaxel, ortataxel, and/or tesetaxel) in a mixture of first and second surfactants. The absorption of the taxane is increased from the pharmaceutical composition is greater than the sum of the absorption of docetaxel from either the first or the second surfactant. The increase in absorption is especially enhanced when the ratio of the first surfactant to the second surfactant in the pharmaceutical composition is between 60:40 and 85:15 by weight, and the total surfactant weight does not exceed 98% of the total weight. Polysorbate 80, polysorbate 20, and caprylocaproyl polyoxylglycerides serve as suitable first surfactants, and polysorbate 80 or polyethyoxylated castor oil serve as suitable second surfactants. The stability of the pharmaceutical composition may be enhanced by further including a stabilizer (e.g., citric acid and/or ascorbic acid).

Abstract: An antiperspirant stick composition can include a synthetic wax having a melting point of less than or equal to 90° C., a melting point additive present at a weight ratio to the synthetic wax to provide the composition with a melting point greater than or equal to 40° C., an effective amount of an antiperspirant active agent, and less than 2 wt % hydrogenated oils, petrolatum, 12-hydroxystearic acid, polyethylenes having a melting point greater than or equal to 60° C., and combinations thereof.

Abstract: Disclosed is a laevorotatory enantiomer of the configurational stereoisomer of difethialone, named homo-stereoisomer, the formula of which is 3-(4?-bromobiphenyl-4-yl)-1-(4-hydroxythiocoumarin-3-yl)-1,2,3,4-tetrahydronaphthalene, in which carbons 1 and 3 of the 1,2,3,4-tetrahydronaphthalene group have the same absolute configuration.

Abstract: A composite material for bone repair based on a decellularized biological tissue matrix material and a preparation method thereof. The composite material for bone repair comprises an organic phase of a microfibrillar decellularized animal tissue matrix material and an inorganic phase of a calcium salt bioceramic or other inorganic bioglass. A preparation process for the composite material for bone repair does not need physical or chemical crosslinking. The composite material for bone repair has a three-dimensional porous network structure, and protein components in the biological tissue matrix material maintain a natural triplex structure. The composite material for bone repair has excellent biocompatibility, biodegradability, osteoconductivity, osteoinductivity, and osteogenecity, also has certain mechanical strength and shape memory function, and can be used as a bone filling material or a repair material for large-area bone defect.